FOOTHILL RANCH, Calif., June 29, 2022--(BUSINESS WIRE)--TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today presented in vivo and in vitro boron delivery data using the company’s novel compounds at the 60th Particle Therapy Co-Operative Group (PTCOG) Conference, occurring June 27 – July 2, 2022.
"The identification of these targeted drugs as alternatives to boron phenylalanine (BPA) coupled with the development of a modern neutron source have the potential to provide a paradigm shift in cancer treatment," said Bruce Bauer, PhD, CEO of TAE Life Sciences. "We are committed to developing BNCT as a treatment modality for difficult to treat tumors and bringing new hope to patients."
Title: Development of a novel accelerator system and new targeted drugs for BNCT
Abstract Number: PTC60-0255
Session Title: Boron Neutron Capture Therapy
Presenter(s): Michael Sandhu, Vice President of Business Development, EMEA, TAE Life Sciences
Date: Wednesday, June 29, 2022
Time: 17:51 – 17:59
BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. BNCT differs radically from other radiation therapy and shows promise in becoming the next-generation cancer treatment. Research has shown BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT’s potential to improve patient care while also improving treatment economics. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.
About TAE Life Sciences
TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to cancer patients who need it most. TLS’s target drugs and neutron radiation system are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005062/en/